)
Visual
test
Xspray Pharma
Xspray Pharma (XSPRAY) investor relations material
Xspray Pharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Feb, 2026
Executive summary
Transitioned from a research-focused to a commercial-stage pharmaceutical company, preparing for US launches of two cancer drugs in 2026.
Faced regulatory challenges, including an FDA Complete Response Letter for Dasynoc® due to manufacturing deficiencies not directly related to its production line.
Continued engagement with FDA and key opinion leaders, with positive clinical feedback and strong market interest in product candidates.
Financial highlights
Net sales were SEK 0 thousand for both Q4 and full year 2025, unchanged from the prior year.
Loss before income tax improved to SEK -37,009 thousand in Q4 2025 (from -82,002) and SEK -171,546 thousand for the year (from -285,674).
Earnings per share before dilution improved to SEK -0.89 in Q4 (from -2.36) and SEK -4.46 for the year (from -8.62).
Cash and cash equivalents at year-end were SEK 153,745 thousand (down from 208,236).
Cash flow from operating activities was SEK -41,370 thousand in Q4 and SEK -193,163 thousand for the year.
Outlook and guidance
Preparing for potential US launches of Dasynoc® and XS003 nilotinib in the second half of 2026.
Cash position expected to finance operations through autumn 2026; additional capital may be sought to support commercialization.
Regulatory resubmission for Dasynoc® planned for Q1 2026; FDA decision on XS003 expected by June 18, 2026.
Update on financing options beyond autumn 2026
Status of contract manufacturer re-inspection
How will Xspray capture CML market share?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Xspray Pharma
- Losses narrowed and liquidity improved, but regulatory and financing risks persist.XSPRAY
Q3 20255 Nov 2025 - FDA delays Dacinoc/Dasynoc approval over contract manufacturer GMP issues; resolution expected by Q1 2025.XSPRAYFDA Announcement8 Oct 2025
- DasynocⓇ launch preparations progress, with narrowed losses and new financing secured.XSPRAYQ2 202515 Aug 2025
- DasynocⓇ launch delayed by FDA, but cash position strengthened and pipeline advanced.XSPRAYQ2 202413 Jun 2025
- Losses deepened as Xspray gears up for DasynocⓇ's US launch and secures new financing.XSPRAYQ3 202413 Jun 2025
- FDA feedback delays Dasynoc launch, but no new clinical studies are required.XSPRAYInvestor Update13 Jun 2025
- Q1 2025 loss narrowed as Xspray advances DasynocⓇ toward FDA approval and US launch.XSPRAYQ1 20255 Jun 2025
- Q4 loss widened as Xspray gears up for DasynocⓇ's US launch, with FDA submission delayed.XSPRAYQ4 20245 Jun 2025
Next Xspray Pharma earnings date
Q1 20266 May, 2026
Xspray Pharma
Next Xspray Pharma earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage